Using circulating tumor cells to inform on prostate cancer biology and clinical utility

Jing Li, Simon G. Gregory, Mariano Garcia-Blanco, Andrew J. Armstrong

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Substantial advances in the molecular biology of prostate cancer have led to the approval of multiple new systemic agents to treat men with metastatic castration-resistant prostate cancer (mCRPC). These treatments encompass androgen receptor directed therapies, immunotherapies, bone targeting radiopharmaceuticals and cytotoxic chemotherapies. There is, however, great heterogeneity in the degree of patient benefit with these agents, thus fueling the need to develop predictive biomarkers that are able to rationally guide therapy. Circulating tumor cells (CTCs) have the potential to provide an assessment of tumor-specific biomarkers through a non-invasive, repeatable "liquid biopsy" of a patients cancer at a given point in time. CTCs have been extensively studied in men with mCRPC, where CTC enumeration using the Cellsearch® method has been validated and FDA approved to be used in conjunction with other clinical parameters as a prognostic biomarker in metastatic prostate cancer. In addition to enumeration, more sophisticated molecular profiling of CTCs is now feasible and may provide more clinical utility as it may reflect tumor evolution within an individual particularly under the pressure of systemic therapies. Here, we review technologies used to detect and characterize CTCs, and the potential biological and clinical utility of CTC molecular profiling in men with metastatic prostate cancer.

Original languageEnglish (US)
Pages (from-to)191-210
Number of pages20
JournalCritical Reviews in Clinical Laboratory Sciences
Volume52
Issue number4
DOIs
StatePublished - Jul 4 2015
Externally publishedYes

Fingerprint

Circulating Neoplastic Cells
Tumors
Prostatic Neoplasms
Cells
Biomarkers
Castration
Radiopharmaceuticals
Androgen Receptors
Therapeutics
Tumor Biomarkers
Immunotherapy
Molecular biology
Fueling
Chemotherapy
Biopsy
Molecular Biology
Neoplasms
Technology
Pressure
Bone and Bones

Keywords

  • Androgen receptor
  • biomarker
  • castration resistant prostate cancer
  • EpCAM
  • liquid biopsy
  • microfluidic
  • PSA

ASJC Scopus subject areas

  • Biochemistry, medical
  • Biochemistry, Genetics and Molecular Biology(all)
  • Clinical Biochemistry

Cite this

Using circulating tumor cells to inform on prostate cancer biology and clinical utility. / Li, Jing; Gregory, Simon G.; Garcia-Blanco, Mariano; Armstrong, Andrew J.

In: Critical Reviews in Clinical Laboratory Sciences, Vol. 52, No. 4, 04.07.2015, p. 191-210.

Research output: Contribution to journalArticle

@article{eddf555e27034ae8b2f9299a2ee70d87,
title = "Using circulating tumor cells to inform on prostate cancer biology and clinical utility",
abstract = "Substantial advances in the molecular biology of prostate cancer have led to the approval of multiple new systemic agents to treat men with metastatic castration-resistant prostate cancer (mCRPC). These treatments encompass androgen receptor directed therapies, immunotherapies, bone targeting radiopharmaceuticals and cytotoxic chemotherapies. There is, however, great heterogeneity in the degree of patient benefit with these agents, thus fueling the need to develop predictive biomarkers that are able to rationally guide therapy. Circulating tumor cells (CTCs) have the potential to provide an assessment of tumor-specific biomarkers through a non-invasive, repeatable {"}liquid biopsy{"} of a patients cancer at a given point in time. CTCs have been extensively studied in men with mCRPC, where CTC enumeration using the Cellsearch{\circledR} method has been validated and FDA approved to be used in conjunction with other clinical parameters as a prognostic biomarker in metastatic prostate cancer. In addition to enumeration, more sophisticated molecular profiling of CTCs is now feasible and may provide more clinical utility as it may reflect tumor evolution within an individual particularly under the pressure of systemic therapies. Here, we review technologies used to detect and characterize CTCs, and the potential biological and clinical utility of CTC molecular profiling in men with metastatic prostate cancer.",
keywords = "Androgen receptor, biomarker, castration resistant prostate cancer, EpCAM, liquid biopsy, microfluidic, PSA",
author = "Jing Li and Gregory, {Simon G.} and Mariano Garcia-Blanco and Armstrong, {Andrew J.}",
year = "2015",
month = "7",
day = "4",
doi = "10.3109/10408363.2015.1023430",
language = "English (US)",
volume = "52",
pages = "191--210",
journal = "Critical Reviews in Clinical Laboratory Sciences",
issn = "1040-8363",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Using circulating tumor cells to inform on prostate cancer biology and clinical utility

AU - Li, Jing

AU - Gregory, Simon G.

AU - Garcia-Blanco, Mariano

AU - Armstrong, Andrew J.

PY - 2015/7/4

Y1 - 2015/7/4

N2 - Substantial advances in the molecular biology of prostate cancer have led to the approval of multiple new systemic agents to treat men with metastatic castration-resistant prostate cancer (mCRPC). These treatments encompass androgen receptor directed therapies, immunotherapies, bone targeting radiopharmaceuticals and cytotoxic chemotherapies. There is, however, great heterogeneity in the degree of patient benefit with these agents, thus fueling the need to develop predictive biomarkers that are able to rationally guide therapy. Circulating tumor cells (CTCs) have the potential to provide an assessment of tumor-specific biomarkers through a non-invasive, repeatable "liquid biopsy" of a patients cancer at a given point in time. CTCs have been extensively studied in men with mCRPC, where CTC enumeration using the Cellsearch® method has been validated and FDA approved to be used in conjunction with other clinical parameters as a prognostic biomarker in metastatic prostate cancer. In addition to enumeration, more sophisticated molecular profiling of CTCs is now feasible and may provide more clinical utility as it may reflect tumor evolution within an individual particularly under the pressure of systemic therapies. Here, we review technologies used to detect and characterize CTCs, and the potential biological and clinical utility of CTC molecular profiling in men with metastatic prostate cancer.

AB - Substantial advances in the molecular biology of prostate cancer have led to the approval of multiple new systemic agents to treat men with metastatic castration-resistant prostate cancer (mCRPC). These treatments encompass androgen receptor directed therapies, immunotherapies, bone targeting radiopharmaceuticals and cytotoxic chemotherapies. There is, however, great heterogeneity in the degree of patient benefit with these agents, thus fueling the need to develop predictive biomarkers that are able to rationally guide therapy. Circulating tumor cells (CTCs) have the potential to provide an assessment of tumor-specific biomarkers through a non-invasive, repeatable "liquid biopsy" of a patients cancer at a given point in time. CTCs have been extensively studied in men with mCRPC, where CTC enumeration using the Cellsearch® method has been validated and FDA approved to be used in conjunction with other clinical parameters as a prognostic biomarker in metastatic prostate cancer. In addition to enumeration, more sophisticated molecular profiling of CTCs is now feasible and may provide more clinical utility as it may reflect tumor evolution within an individual particularly under the pressure of systemic therapies. Here, we review technologies used to detect and characterize CTCs, and the potential biological and clinical utility of CTC molecular profiling in men with metastatic prostate cancer.

KW - Androgen receptor

KW - biomarker

KW - castration resistant prostate cancer

KW - EpCAM

KW - liquid biopsy

KW - microfluidic

KW - PSA

UR - http://www.scopus.com/inward/record.url?scp=84940366437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940366437&partnerID=8YFLogxK

U2 - 10.3109/10408363.2015.1023430

DO - 10.3109/10408363.2015.1023430

M3 - Article

C2 - 26079252

AN - SCOPUS:84940366437

VL - 52

SP - 191

EP - 210

JO - Critical Reviews in Clinical Laboratory Sciences

JF - Critical Reviews in Clinical Laboratory Sciences

SN - 1040-8363

IS - 4

ER -